TMEM17: A Transmembrane Protein Identified as a Potential Drug Target and Biomarker

Target Name: TMEM17

NCBI ID: G200728

TMEM17

Other Name(s): transmembrane protein 17 | Transmembrane protein 17 | TMM17_HUMAN

TMEM17: A Transmembrane Protein Identified as a Potential Drug Target and Biomarker

TMEM17 (Transmembrane Protein 17) is a protein that has been identified as a potential drug target and biomarker. It is a member of the TMEM family, which includes other proteins involved in various cellular processes, including cell signaling, cytoskeletal organization, and transport of small molecules across cell membranes.TMEM17 is unique among its family members due to its potential to modulate the activity of several cellular signaling pathways, including the TGF-β pathway.

The TGF-β pathway is a well-established signaling pathway that plays a crucial role in various cellular processes, including cell growth, differentiation, and response to environmental stimuli. It is a complex pathway that involves the engagement of multiple protein interactions, including the binding of the transcription factor SMAD (Sonic Hedgehog), which is critical for cell signaling.

TMEM17 has been shown to play a role in the regulation of TGF-β signaling pathway. It is a negative regulator of the SMAD complex, which means that it promotes the separation of SMAD from the nuclear membrane and limits its ability to interact with SMAD. This process is critical for the normal function of the TGF-β pathway, as SMAD is the primary regulatory protein for TGF-β signaling.

In addition to its role in TGF-β signaling, TMEM17 has also been shown to be involved in the regulation of other cellular signaling pathways, including the ERK signaling pathway, which is involved in the regulation of cell growth and survival.

TMEM17 has also been shown to be a potential biomarker for several diseases, including cancer. Its expression has been observed in various types of cancer, including breast, lung, and ovarian cancer, and has been associated with poor prognosis. This suggests that TMEM17 may be a useful target for cancer therapies that target the TGF-β pathway.

Conclusion

In conclusion, TMEM17 is a unique protein that has been identified as a potential drug target and biomarker. Its role in the regulation of TGF-β signaling pathway and its potential involvement in the regulation of other cellular signaling pathways make it an attractive target for small molecule inhibitors. Further research is needed to determine the full extent of TMEM17's involvement in cellular signaling and its potential as a drug target and biomarker.

Protein Name: Transmembrane Protein 17

Functions: Transmembrane component of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes. Required for ciliogenesis and sonic hedgehog/SHH signaling (By similarity)

The "TMEM17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets